Bladder cancer is the fifth most common cancer with approximately 70-75% being Non-Muscle Invasive (NMIBC) at diagnosis. There is a significant unmet need for efficacious bladder sparing second line treatment options for BCG-unresponsive high risk NMIBC, whether high grade disease or carcinoma in situ (CIS).

Back to Products